1-20 of 52
Jeong A. Kim
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Durability of Complete Responses in Patients from the ECHELON-3 Study

Christopher Yasenchak, Nancy L. Bartlett, Jeong-A Kim, Uwe Hahn, Craig A. Portell, Francesco Zaja, Thorsten Zenz, Cecily Forsyth, Jin Seok Kim, Seok-Goo Cho, Jae-Yong Kwak, Hao-Yuan Wang, Herve Ghesquieres, Grzegorz S. Nowakowski, Monica Patterson, Linda Ho, Evelyn Rustia, Michelle Fanale, Keenan Fenton, Frank Stenner
Journal: Blood
Blood (2024) 144 (Supplement 1): 3101.
https://doi.org/10.1182/blood-2024-194158
Published: 2024
Journal Articles

Outcomes By Refractory Status and Prior Therapies Received in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) from the ECHELON-3 Study

Uwe Hahn, Nancy L. Bartlett, Jeong-A Kim, Krimo Bouabdallah, Nicholas Forward, Tsai-Yun Chen, Vincent Camus, Ming-Chung Wang, Philippe Carassou, Enrico Derenzini, Hung Chang, Fritz Offner, Herve Ghesquieres, Grzegorz S. Nowakowski, Christopher Yasenchak, Monica Patterson, Linda Ho, Evelyn Rustia, Michelle Fanale, Keenan Fenton, Craig A. Portell
Journal: Blood
Blood (2024) 144 (Supplement 1): 4489.
https://doi.org/10.1182/blood-2024-200914
Published: 2024
Journal Articles

Outcomes in Older Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) from the ECHELON-3 Study

Nancy L. Bartlett, Jeong-A Kim, Uwe Hahn, Isabelle Fleury, Kamel Laribi, Juan Miguel Bergua Burgues, Craig A. Portell, Melina Boutin, Blanca Sanchez Gonzalez, Selay Lam, Sung Yong Oh, Judit Mészáros Joergensen, Young Rok Do, Herve Ghesquieres, Grzegorz S. Nowakowski, Christopher Yasenchak, Monica Patterson, Linda Ho, Evelyn Rustia, Michelle Fanale, Keenan Fenton, Vincent Ribrag
Journal: Blood
Blood (2024) 144 (Supplement 1): 4483.
https://doi.org/10.1182/blood-2024-200836
Published: 2024
Journal Articles

Low Dose Fludarabine Is an Effective Conditioning Treatment to Suppress Relapse Rate in PT-CY-Based Haploidentical Peripheral Blood Stem Cell Transplantation

Jeong-A Kim, Jinhang Kim, Nanyoung Yun, Misuk Yang, Youngeun Jung
Journal: Blood
Blood (2024) 144 (Supplement 1): 510.
https://doi.org/10.1182/blood-2024-209588
Published: 2024
Journal Articles

Tumor-Primed CD3 + CD56 + natural Killer T-like Cells As an Efficient Novel Cell Therapy for Relapsed/Refractory Multiple Myeloma

Ji Hyun Lee, Seok-Ho Kim, Junsang Doh, Duck Cho, Jeong-a Kim, Sung Yong Oh, Sung-Hyun Kim, Juheon Lee
Journal: Blood
Blood (2024) 144 (Supplement 1): 2057.
https://doi.org/10.1182/blood-2024-200559
Published: 2024
Journal Articles

Coexpression of Tim-3 and PD-1 of T Lymphocytes Prevents Acute Graft-Versus-Host Disease

Jeong-A Kim, Jinhang Kim, Saetbyeol Kim, Misuk Yang
Journal: Blood
Blood (2023) 142 (Supplement 1): 4796.
https://doi.org/10.1182/blood-2023-190640
Published: 2023
Journal Articles

Risk Stratification for Elderly Patients with Diffuse Large B-Cell Lymphoma Integrating Simplified Geriatric Assessment: A Prospective, Multicenter, Cohort Study

Ho-Young Yhim, Yong Park, Jeong-A Kim, Ho-Jin Shin, Young Rok Do, Joon Ho Moon, Min Kyoung Kim, Won Sik Lee, Dae Sik Kim, Myung-Won Lee, Yoon Seok Choi, Seong Hyun Jeong, Kyoung Ha Kim, Chang-Hoon Lee, Ga-Young Song, Jae-Yong Kwak, Deok-Hwan Yang
Journal: Blood
Blood (2022) 140 (Supplement 1): 6719–6720.
https://doi.org/10.1182/blood-2022-159929
Published: 2022
Journal Articles

Ex Vivo Culture with Albumin Greatly Increases the Immunosuppressive Subset of T Lymphocytes

Jeong-A Kim, Jinhang Kim, Saetbyeol Kim, Misuk Yang, Youngrok Park, Jae-Yong Kwak
Journal: Blood
Blood (2022) 140 (Supplement 1): 4538–4539.
https://doi.org/10.1182/blood-2022-163010
Published: 2022
Journal Articles

Ex Vivo IL-2 Treatment Increases the Immunosuppressive Subset of T Lymphocytes to Suppress Allo-Immune Response

Jeong-A Kim, Jinhang KIM, Misuk Yang, Youngrok Park, Jae-Yong Kwak
Journal: Blood
Blood (2021) 138 (Supplement 1): 2066.
https://doi.org/10.1182/blood-2021-152462
Published: 2021
Journal Articles

Second Imatinib Discontinuation Outcomes in Patients Regaining Durable Deep Molecular Response in the Korean Imatinib Discontinuation Study; KID Study

Sung-Eun Lee, MD PhD, Joon Seong Park, MD, Young Rok Do, PhDMD, Sung-Hyun Kim, MD PhD, Dae Young Zang, MDPhD, Sukjoong Oh, MDPhD, Jae-Yong Kwak, Jeong-A Kim, Yeung-Chul Mun, MD, Won Sik Lee, MD PhD, Dong-Wook Kim, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 51–52.
https://doi.org/10.1182/blood-2020-139253
Published: 2020
Journal Articles

Long-Term Outcomes of Chronic Myeloid Leukemia Patients Who Lost Undetectable Molecular Residual Disease (UMRD) after Imatinib Discontinuation: Korean Imatinib Discontinuation Study (KIDS)

Sung-Eun Lee, MD, Joon Seong Park, MD, Hyeoung-Joon Kim, MD PhD, Sung-Hyun Kim, MD PhD, Dae Young Zang, MD PhD, Sukjoong Oh, MD PhD, Young Rok Do, PhDMD, Yunsuk Choi, MD, Jae-Yong Kwak, MD PhD, Jeong-A Kim, MD PhD, Kyoo Hyung Lee, MD PhD, Yeung-Chul Mun, MD, Won Sik Lee, MD PhD, Myung Hee Chang, MD, Jinny Park, MD PhD, Jihyun Kwon, MD, Dong-Wook Kim
Journal: Blood
Blood (2019) 134 (Supplement_1): 1643.
https://doi.org/10.1182/blood-2019-126376
Published: 2019
Journal Articles

Pigment Epithelium-Derived Factor Promotes the Angiogenic Activity of VEGF

Jeong-A Kim, MD PhD, Misuk Yang, Young Hoon Park, MD, Youngrok Park, Jae-Yong Kwak, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3687.
https://doi.org/10.1182/blood-2018-99-117420
Published: 2018
Journal Articles

Final Study Results of Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase (CML-CP) Patients Receiving Radotinib 300 Mg BID or Imatinib: Rerise 48 Months Follow-up

Young Rok Do, PhDMD, Jae-Yong Kwak, MD PhD, Hawk Kim, MDPhD, Jeong-A Kim, MD PhD, Hyeoung-Joon Kim, MD PhD, Joon Seong Park, MD, Jooseop Chung, MD PhD, Ho-Jin Shin, MD PhD, Sung-Hyun Kim, MD PhD, Udomsak Bunworasate, MD, Chul Won Choi, MD PhD, Narcisa Sonia Cornejo Comia, MD, Dae Young Zang, MDPhD, Sukjoong Oh, MDPhD, Saengsuree Jootar, MD, Ary Harryanto Reksodiputro, MDPhD, Won-Sik Lee, MD, Yeung-Chul Mun, MD PhD, Jee Hyun Kong, MD, Priscilla B. Caguioa, MD, Jinny Park, MD PhD, Chul W. Jung, MD PhD, Dong-Wook Kim, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1733.
https://doi.org/10.1182/blood-2018-99-110568
Published: 2018
Journal Articles

Characterization of ABL Compound Mutation Using Sanger and Subcloning Sequencing in Tyrosine Kinase Inhibitor Resistant Chronic Myeloid Leukemia

Sukjoong Oh, Ki Hoon Kang, Won-Sik Lee, MD PhD, Hyeoung-Joon Kim, Jee Hyun Kong, Yunsuk Choi, MD, Young Rok Do, MD PhD, Jae-Yong Kwak, Sung-Hyun Kim, MD PhD, Jeong-A Kim, Dae Young Zang, MD PhD, Yeung-Chul Mun, MD PhD, Young-Woong Won, Sung-Eun Lee, MD, Dong-Wook Kim, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2864.
https://doi.org/10.1182/blood.V130.Suppl_1.2864.2864
Published: 2017
Journal Articles

The Impact of Early Molecular Response at 3 Months on Long-Term Survival Was Enhanced in the CP CML Patients Treated with Second-Generation Tyrosine Kinase Inhibitors

Sung-Eun Lee, MD, Won-Sik Lee, MD PhD, Hyeoung-Joon Kim, Jee Hyun Kong, Yunsuk Choi, MD, Young Rok Do, MD PhD, Jae-Yong Kwak, Sukjoong Oh, Sung-Hyun Kim, MD PhD, Jeong-A Kim, Dae Young Zang, Yeung-Chul Mun, MD PhD, Young-Woong Won, Dong-Wook Kim, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2873.
https://doi.org/10.1182/blood.V130.Suppl_1.2873.2873
Published: 2017
Journal Articles

Very Early Molecular Response at 1 Month Is a Predictor of the Outcome of Chronic Phase Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors

Won-Sik Lee, MD PhD, Hye-Young Song, Hyeoung-Joon Kim, Jee Hyun Kong, Young Rok Do, MD PhD, Jae-Yong Kwak, Sukjoong Oh, Sung-Hyun Kim, MD PhD, Jeong-A Kim, Dae Young Zang, MD PhD, Yeung-Chul Mun, MD PhD, Young-Woong Won, Sung-Eun Lee, MD, Yunsuk Choi, MD, Dong-Wook Kim, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1593.
https://doi.org/10.1182/blood.V130.Suppl_1.1593.1593
Published: 2017
Journal Articles

Fractalkine Treated of CD11b + CX3CR1 + Monocytes Promotes Angiogenesis through Pigment Epithelium-Derived Factor

Jeong-A Kim, Jae-Yong Kwak, Joon Lee, Youngrok Park, Hal E. Broxmeyer, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1026.
https://doi.org/10.1182/blood.V130.Suppl_1.1026.1026
Published: 2017
Journal Articles

Deeper Molecular Response in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase (CML-CP) Patients Receiving Radotinib 300 Mg BID or Imatinib: Rerise 36 Months Follow-up

Young Rok Do, MD PhD, Hawk Kim, MD PhD, Jae-Yong Kwak, Jeong-A Kim, Hyeoung-Joon Kim, Joon Seong Park, MD, Jooseop Chung, MD PhD, Ho-Jin Shin, MD PhD, Sung-Hyun Kim, MD PhD, Udomsak Bunworasate, MD, Chul Won Choi, MD PhD, Narcisa Sonia Cornejo Comia, MD, Dae Young Zang, Sukjoong Oh, Saengsuree Jootar, MD, Ary Harryanto Reksodiputro, MDPhD, Won-Sik Lee, MD, Yeung-Chul Mun, MD PhD, Jee Hyun Kong, Priscilla B. Caguioa, MD, Jinny Park, MD PhD, Chul W. Jung, MD PhD, Dong-Wook Kim, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 317.
https://doi.org/10.1182/blood.V130.Suppl_1.317.317
Published: 2017
Journal Articles

A Phase II Trial of Bendamustine, Carboplatin and Dexamethasone (BCD) for Refractory or Relapsed Peripheral T-Cell Lymphoma (BENCART): A Consortium for Improving Survival of Lymphoma (CISL) Trial

Byeong-Bae Park, Won Seog Kim, Cheolwon Suh, Dok Hyun Yoon, Jong-Ho Won, Deok-Hwan Yang, Young-Rok Do, Won Sik Lee, Jeong-A Kim, Min Kyoung Kim, Jae-Cheol Jo, MD PhD, Youngil Koh, MD PhD
Journal: Blood
Blood (2016) 128 (22): 1823.
https://doi.org/10.1182/blood.V128.22.1823.1823
Published: 2016
Journal Articles

Fractalkine/CX3CR1 Signaling Promotes Angiogenic Potentials in CX3CR1 Expressing Monocytes

Jeong A Kim, MD PhD, Jae-Yong Kwak, MD PhD, Yhim Eunjung, MD, Joon Lee, Youngrok Park, Hal E. Broxmeyer, PhD
Journal: Blood
Blood (2016) 128 (22): 2507.
https://doi.org/10.1182/blood.V128.22.2507.2507
Published: 2016